METHODS: The study was performed in 89 paired tissue specimens and plasma samples obtained from NSCLC patients who underwent surgical treatment at the Department of Thoracic Surgery and Oncology of the National Cancer Institute. Analysis of miR-181a-5p and miR-630 expression was performed by qRT-PCR using TaqMan miRNA specific primers. Whereas BCL2, LMO3, PTEN, SNAI2, WIF1 expression levels were identified with KAPA SYBR FAST qPCR Kit. Each sample was examined in triplicate and calculated following the 2-ΔΔCt method. When the p-value was less than 0.05, the differences were considered statistically significant.
RESULTS: It was found that miR-181a-5p and miR-630 expression levels in NSCLC tissue and plasma samples were significantly decreased compared with control samples. Moreover, patients with low miR-181a-5p expression in tumor tissue and plasma had longer PFS rates than those with high miRNA expression. Decreased miR-630 expression in tumor was statistically significantly associated with better NSCLC patients\' OS. In addition, the expression of miR-181a-5p, as well as miR-630 in tumor tissue, are the statistically significant variables for NSCLC patients\' OS. Moreover, in NSCLC patient plasma samples circulating miR-181a-5p can be evaluated as significant independent prognostic factors for OS and PFS.
CONCLUSIONS: Our findings indicate the miR-181a-5p and miR-630 expression levels have the potential to prognose and predict and therefore improve the treatment individualization and the outcome of NSCLC patients. Circulating miR-181a-5p has the potential clinical value as a non-invasive biomarker for NSCLC.
方法:该研究是在美国国家癌症研究所胸外科和肿瘤科接受手术治疗的NSCLC患者中获得的89个配对组织样本和血浆样本中进行的。使用TaqManmiRNA特异性引物通过qRT-PCR进行miR-181a-5p和miR-630表达的分析。而BCL2,LMO3,PTEN,SNAI2、WIF1表达水平用KAPASYBRFASTqPCR试剂盒鉴定。每个样品一式三份检查并按照2-ΔΔCt方法计算。当p值小于0.05时,认为差异具有统计学意义。
结果:发现与对照样品相比,NSCLC组织和血浆样品中的miR-181a-5p和miR-630表达水平显着降低。此外,miR-181a-5p在肿瘤组织和血浆中低表达的患者比miRNA高表达的患者具有更长的PFS率.肿瘤中miR-630表达降低与NSCLC患者更好的OS显著相关。此外,miR-181a-5p的表达,以及肿瘤组织中的miR-630,是NSCLC患者OS的统计学显著变量。此外,在NSCLC患者血浆样本中,循环miR-181a-5p可被评估为OS和PFS的显著独立预后因素.
结论:我们的发现表明miR-181a-5p和miR-630表达水平具有预测和预测的潜力,因此可以改善NSCLC患者的个体化治疗和预后。循环miR-181a-5p作为NSCLC的非侵入性生物标志物具有潜在的临床价值。